J. S. Madero

发表

Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.

D. Niewoehner, J. Connett, J. Vestbo, 2016, The Lancet. Respiratory medicine.

Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean

P. Cahn, V. Fink, J. Pape, 2015, Journal of the International AIDS Society.

Duration of Anti-Tuberculosis Therapy and Timing of Antiretroviral Therapy Initiation: Association with Mortality in HIV-Related Tuberculosis

D. Masys, T. Sterling, C. César, 2013, PLoS ONE.

Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy

W. Wester, T. Sterling, P. Cahn, 2022, BMC Infectious Diseases.

Relationship Between Anemia and Systemic Inflammation in People Living With HIV and Tuberculosis: A Sub-Analysis of the CADIRIS Clinical Trial

M. Lederman, B. Andrade, I. Sereti, 2022, Frontiers in Immunology.

Metabolic Profiles of Individuals Switched to Second-Line Antiretroviral Therapy after Failing Standard First-Line Therapy for Treatment of HIV-1 Infection in a Randomized, Controlled Trial

D. Cooper, S. Kerr, S. Emery, 2017, Antiviral therapy.

Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies

J. Rockstroh, P. Cahn, A. Antinori, 2020, Journal of Infection and Public Health.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

B. Gazzard, K. Tashima, M. Shields, 2019, The Lancet.

Rates and Reasons for Early Change of First HAART in HIV-1-Infected Patients in 7 Sites throughout the Caribbean and Latin America

D. Masys, P. Cahn, V. Fink, 2010, PloS one.

Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study.

P. Cahn, V. Fink, O. Sued, 2015, The lancet. HIV.

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.

K. Ruxrungtham, D. Cooper, H. Teppler, 2015, The lancet. HIV.

Mortality During the First Year of Potent Antiretroviral Therapy in HIV-1-Infected Patients in 7 Sites Throughout Latin America and the Caribbean

D. Masys, P. Cahn, J. Pape, 2009, Journal of acquired immune deficiency syndromes.

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

J. Rockstroh, P. Cahn, A. Antinori, 2019, Journal of acquired immune deficiency syndromes.

2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.

B. Gazzard, R. Kaiser, B. Larder, 2021, The Journal of antimicrobial chemotherapy.

2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings

Dechao Wang, Shanmugam Saravanan, John Baxter, 2018, The Journal of antimicrobial chemotherapy.

Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection.

R. Paredes, H. Furrer, A. Phillips, 2023, NEJM evidence.

Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection.

M. Lederman, H. Valdez, C. Lange, 2002, Journal of acquired immune deficiency syndromes.

Detection and management of drug-resistant tuberculosis in HIV-infected patients in lower-income countries.

G. Gottlieb, J. Stringer, C. Yiannoutsos, 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

T. Harrer, A. Winston, E. Harrer, 2023, Scientific Reports.

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.

K. Ruxrungtham, D. Cooper, H. Teppler, 2015, The lancet. HIV.